However Pfizer's short interest can also be evaluated against the total number of Pfizer shares, or, against the total number of tradable Pfizer shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In other words for every 100,000 Pfizer shares traded daily on the market, roughly 2210 shares are currently held short. Pfizer's "short interest ratio" (SIR) is the quantity of Pfizer shares currently shorted divided by the average quantity of Pfizer shares traded daily (recently around 24.7 million). There are a few different ways that this level of interest in shorting Pfizer shares can be evaluated. This figure is 0.7% up from 54.1 million last month. There are currently 54.5 million Pfizer shares held short by investors – that's known as Pfizer's "short interest". TTM: trailing 12 months Shorting Pfizer shares The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.
![pfizer share price pfizer share price](https://img.currency.com/articles/-GRAPH-Pfizer-December-2020-Forecast.jpg)
Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$20.1 billion (£14.9 billion). By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies. The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
![pfizer share price pfizer share price](https://www.schroders.com/en/sysglobalassets/digital/insights/2021/04-april-2021/whos-making-money-from-covid-19-vaccines/vaccine-makers-601032.jpg)
Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7302. The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued. That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). In other words, Pfizer shares trade at around 19x recent earnings. Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. However, analysts commonly use some key metrics to help gauge the value of a stock. Valuing Pfizer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfizer's overall performance. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock. Optimise your portfolio by tracking how your stock - and even the business - performs with an eye on the long term. Congratulations, you own a part of Pfizer. You may be able to buy a fractional share of Pfizer, depending on your broker. At last close price of US$43.18, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts. Buy today with a market order or use a limit order to delay your purchase until Pfizer reaches your desired price. Research its history to confirm it's a solid investment against your financial goals. Find the share by name or ticker symbol: PFE. Fund your account with a bank transfer, credit card or debit card.
![pfizer share price pfizer share price](https://i.dailymail.co.uk/1s/2020/11/11/16/35561952-8938065-image-a-51_1605113086312.jpg)
Complete an application with your personal and financial details, like your ID and tax file number. If you're just starting out, look for a platform with low brokerage and foreign exchange fees. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. Its main areas of healthcare include internal medicine, oncology, inflammation, immunology, rare diseases and consumer healthcare. It is a well-known brand that develops and markets medicines such as Viagra and Lipitor. It has seen a rise in profits since the release of its COVID-19 vaccine early in 2021. (NYSE: PFE) is a research-based global biopharmaceutical company based in the US.